-transparent.png){kind=logo}
OBJECTIVE To determine the prevalence and meaning of antibodies to the hepatitis C virus (HCV) in patients with nonalcoholic chronic liver diseases. METHODS Cross-sectional study. METHODS The liver unit of a referral-based university hospital. METHODS Three hundred and forty-six consecutive patients, including 137 with cryptogenic chronic liver disease, 156 with chronic hepatitis B, 47 with primary biliary cirrhosis, and 8 with persistently abnormal aminotransferase serum levels and normal liver histology. Among patients with cryptogenic liver disease, 41 received blood transfusions before discovery of liver disease and 18 had circulating nonorgan-specific autoantibodies. For comparison, 1495 apparently healthy volunteer blood donors were included in the study. LABORATORY INVESTIGATIONS: The presence of anti-HCV antibodies (anti-HCV) was determined by a recently developed enzyme-linked immunoassay. RESULTS In patients with cryptogenic liver disease, the prevalence of anti-HCV was 82% (95% CI, 76% to 89%), being higher (P = 0.02) in patients with histories of blood transfusion than in those with unknown sources of exposure. Antibodies to HCV were not detected in patients with antinuclear antibodies at high titer. Among patients with chronic hepatitis B, anti-HCV were found in 11% (CI, 5% to 18%) of those with hepatitis B virus (HBV)-associated DNA in serum and in 29% (CI, 17% to 43%) of those with undetectable HBV replication (P less than 0.05). The prevalence of anti-HCV in blood donors was 1.2% (CI, 1.1% to 1.3%). CONCLUSIONS Our results indicate that HCV infection probably plays an important etiologic role in cryptogenic liver disease and, in some patients, in chronic hepatitis B. Determining whether anti-HCV are present appears to be useful for differentiating viral from autoimmune chronic liver diseases.
J M Sánchez-Tapias, and
J M Barrera, and
J Costa, and
M G Ercilla, and
A Parés, and
L Comalrrena, and
F Soley, and
J Bruix, and
X Calvet, and
M P Gil
September 1995,
Nihon rinsho. Japanese journal of clinical medicine,
J M Sánchez-Tapias, and
J M Barrera, and
J Costa, and
M G Ercilla, and
A Parés, and
L Comalrrena, and
F Soley, and
J Bruix, and
X Calvet, and
M P Gil
July 1999,
The New England journal of medicine,
J M Sánchez-Tapias, and
J M Barrera, and
J Costa, and
M G Ercilla, and
A Parés, and
L Comalrrena, and
F Soley, and
J Bruix, and
X Calvet, and
M P Gil
March 2008,
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
J M Sánchez-Tapias, and
J M Barrera, and
J Costa, and
M G Ercilla, and
A Parés, and
L Comalrrena, and
F Soley, and
J Bruix, and
X Calvet, and
M P Gil
April 2009,
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi,
J M Sánchez-Tapias, and
J M Barrera, and
J Costa, and
M G Ercilla, and
A Parés, and
L Comalrrena, and
F Soley, and
J Bruix, and
X Calvet, and
M P Gil
May 1994,
Annals of internal medicine,
J M Sánchez-Tapias, and
J M Barrera, and
J Costa, and
M G Ercilla, and
A Parés, and
L Comalrrena, and
F Soley, and
J Bruix, and
X Calvet, and
M P Gil
July 1991,
Gastroenterologia Japonica,
J M Sánchez-Tapias, and
J M Barrera, and
J Costa, and
M G Ercilla, and
A Parés, and
L Comalrrena, and
F Soley, and
J Bruix, and
X Calvet, and
M P Gil
October 1992,
Gastroenterologia Japonica,
J M Sánchez-Tapias, and
J M Barrera, and
J Costa, and
M G Ercilla, and
A Parés, and
L Comalrrena, and
F Soley, and
J Bruix, and
X Calvet, and
M P Gil
June 2003,
Clinical transplantation,
J M Sánchez-Tapias, and
J M Barrera, and
J Costa, and
M G Ercilla, and
A Parés, and
L Comalrrena, and
F Soley, and
J Bruix, and
X Calvet, and
M P Gil
December 2018,
Minerva gastroenterologica e dietologica,
J M Sánchez-Tapias, and
J M Barrera, and
J Costa, and
M G Ercilla, and
A Parés, and
L Comalrrena, and
F Soley, and
J Bruix, and
X Calvet, and
M P Gil
August 2008,
Clinics in liver disease,
